Antibacterials
The powerful broad-spectrum phage COP-01/20 cocktail was developed to treat multidrug-resistant Staphylococcus epidermidis infections. Careful COP-01/20 phage selection and purification process provide excellent efficiency and safety profile.
| Name | Target | Stage development pre-clinical clinical trial |
|---|---|---|
| COP-01/20 | multidrug-resistant S. epidermidis | pre-clinical |
- Activity against multidrug-resistant S. epidermidis
- Penetrating biofilms
- Stability
- Superior manufacturing process
COP-01/20 is a cocktail of stabilized bacteriophages for treatment of Staphylococcus epidermidis infections. S. epidermidis, the most abundant microbe of normal commensal flora of human skin and mucous membranes is the most common cause of primary bacteremia and infections of indwelling medical devices.
COP-01/20 has a broad host range and synergistic activity with antibiotics against S. epidermidis biofilms in vitro.
Contact: biotech@cobik.si
Collaborations
Partner for hospital use of products in pre-clinical testing: UK Phage therapy.
